A new FDA warning
The FDA said it had found evidence of a potential increased risk of a rare eye condition and required the makers of all GLP-1 medications to add a safety warning. The agency stressed that the condition is rare and that a causal relationship has not been established.
NAION is caused by decreased blood flow to the front part of the optic nerve and can result in sudden decreased vision, including permanent vision loss; its underlying cause is not fully understood.
According to the FDA, NAION cases have been reported for all currently marketed GLP-1 products.
















